Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2013

View Archived Issues

The development and validation of a clinical integrative model for sepsis prognosis

Kancera provides update on R&D programs

Second-generation Mdm2 inhibitor shows promise in cancer models

The development of new animal models for the study of human prion diseases

Phase II clinical evaluation of an inhaled antibiotic in patients with lung disease

Cellular Biomedicine completes enrollment for phase I trial of TC-DC therapy for liver cancer

No safety concerns to date in phase III trial of NX-1207

Athera and Medirista sign agreement for the Annexin A5 project

Seahorse Bioscience and Cancer Research UK Beatson Institute to study cancer metabolism

Novartis ships influenza vaccines to U.S. market for the 2013-2014 season

Korean researchers disclose new DGAT1 inhibitors

New MGPEG-2 inhibitors presented by Glenmark Pharmaceutical

Researchers at Merck KGaA patent novel PARP-1/TANK inhibitors

Merck KGaA discloses new TBK1 and IKK-epsilon inhibitors

Eolas Therapeutics divulges novel OX1/OX2 receptor antagonists

Navidea Biopharmaceuticals reaches agreement with the FDA on imaging agent

OrphanPacific launches Normosang in Japan for acute hepatic porphyria

Immune Pharmaceuticals and EpiCept complete merger

Pomalidomide receives orphan drug status for the treatment of systemic sclerosis

FDA approves Valchlor gel for early-stage mycosis fungoides-type CTCL

NIH to fund UCLA alcoholism study of MediciNova's MN-166

Amgen's acquisition of Onyx Pharmaceuticals approved by boards of directors

GSK's SHIELD-1 vercirnon study in Crohn's disease fails to meet primary endpoint

Novavax acquires Isconova

CardioCel receives CE mark approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...